The current market price of Nippon India NIFTY Pharma ETF Growth Plan is ₹27.14. ETF prices fluctuate during market hours based on demand, supply, and movements in the underlying index or assets.

Nippon India NIFTY Pharma ETF Growth Plan, managed by Nippon Life India Asset Management Limited, is an Equity ETF employing a passive approach to track the Nifty Pharma TRI proportionally. It tracks Nifty Pharma TRI via passive proportional replication, targeting low tracking error of 0.0% and aiming close benchmark alignment through full index weight replication and minimal cash buffer levels. Portfolio is heavily pharmaceutical with Pharmaceuticals & Biotechnology at 99.9%, top holding Sun Pharmaceutical Industries at 21.3%, top five concentration about 56.3%, equity allocation 99.9% and cash 0.1% underscoring concentration. Performance shows 1Y return of +17.6%, reflecting sector strength and close benchmark replication, with tracking error low at 0.0% which supports efficient index tracking and consistent replication over time. Operationally the ETF had AUM of ₹1007.5 Cr as on Jan 2026, monthly average ₹1007.0 Cr, expense ratio 0.2%, fund manager Jitendra Tolani since Feb 2025 with 19 years' experience.

Nippon India NIFTY Pharma ETF Growth Plan is designed to track Nifty Pharma TRI, allowing investors to gain exposure to its underlying securities through a single investment.

The expense ratio of Nippon India NIFTY Pharma ETF Growth Plan is 0.18%. This represents the annual fee charged by the fund house for managing the ETF and is deducted from the fund’s assets.

The Assets Under Management (AUM) of Nippon India NIFTY Pharma ETF Growth Plan is approximately ₹1,570.17. AUM reflects the total market value of assets managed by the ETF and is often used as an indicator of fund size and liquidity.

Nippon India NIFTY Pharma ETF Growth Plan is classified under the as per the risk-o-meter defined by the fund house risk category. The risk level depends on the volatility of the underlying index, market conditions, and asset composition of the ETF.

The tracking error of Nippon India NIFTY Pharma ETF Growth Plan is 0.02%. Tracking error measures how closely the ETF’s performance matches its benchmark index over time.

Nippon India NIFTY Pharma ETF Growth Plan has a dividend yield of 0.67%. Dividend treatment depends on the ETF structure and fund house policy.

Based on available data, Nippon India NIFTY Pharma ETF Growth Plan has delivered the following returns: 1-year return: 21.49%. 3-year return: 21.49%. 5-year return: 21.49%. Past performance does not guarantee future results.

Before investing in Nippon India NIFTY Pharma ETF Growth Plan, investors generally consider the underlying index, expense ratio, tracking error, risk profile, liquidity, and how the ETF fits within their overall portfolio strategy.